Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice

Table 1 Baseline characteristics of patients started on MVC treatment.

Characteristics	Group A¹ n = 25	Group B² n = 7	All patients n = 32
Gender (f/m)	6/19	2/5	8/24
Median age at start MVC (years)	47	48	47
Median CD4⁺ T count at baseline	364	235	306.5
Median VL at baseline	829	< 50 copies/ml	280
Median number of previous drug combinations*	9	10	9
Median duration of previous antiretroviral therapy (years) *	10.2	8.5	10.1
Percentage with CCS of OBT ≥ 2	20/25	5/7	25/32
	(80%)	(71%)	(78%)
Median CCS of OBT	2.5	2.0	2.5

*Salvage drugs included darunavir, raltegravir, etravirine, enfuvirtide, and tipranavir (DRV, RAL, ETR, ENF and TPV). CCS = cumulative sensitivity score, ¹HIV-RNA detectable at screening, ²HIV-RNA not detectable at screening.

ISSN: 2047-783X